This was President Trump’s first week back in the Oval Office. Along with issuing a flurry of executive orders, his administration has imposed a range of restrictions on the National Institutes of ...

Healthpeak reported first-quarter results that were slightly better than we anticipated, leading us to reaffirm our $33.50 fair value estimate for the no-moat company. Same-store net operating income, ...

Narrow-moat Merck KGaA's fourth-quarter results reflected continued challenges in its life science and semiconductor end markets. The firm generated results within its target ranges for 2023, albeit a ...